Richard Aplenc, MD, MSCE
| Office Location | 4018 CTRB, CHOP |
| raplenc@mail.med.upenn.edu | |
| Personal Website | http://www.chop.edu/consumer/pat_care_fam_serv/staff_profile_page.jsp?id=47916 |
Faculty Information | |
| CCEB Appointment | Associate Scholar, Epidemiology |
| Primary Faculty Appointment | Assistant Professor of Pediatrics, University of Pennsylvania Perelman SOM/CHOP |
Research Statement
My research interests center on three areas: molecular epidemiology, pediatric cancer Phase I clinical trials, and the treatment of pediatric AML. My epidemiology research centers on the use of genetic polymorphism data to predict treatment response to therapeutic interventions, particularly in pediatric cancer therapy. These research efforts focus on two active case-control studies in pediatric ALL. The first study examines genotypes in drug metabolizing enzymes and treatment outcome on the Children’s Cancer Group national acute lymphoblastic leukemia trial, CCG-1891. The second study evaluates genotypes and treatment response on CCG-1961, which was the follow up leukemia trial to CCG-1891. This work is funded by an R01 from the National Cancer Institute.
I currently serve as the local PI for Children’s Hospital of Philadelphia in the Phase I Consortium. Within the Phase I Consortium, I am the study chair for ADVL0516, a phase I trial of Dasatinib in children with refractory solid tumors and gleevec resistant leukemias.
My clinical research in acute myeloid leukemia centers on clinical trials and participation in the AML strategy group within COG. I am the vice-chair of the upcoming Phase III trial for de novo AML patients, AAML0531. I am also leading the development of the Phase III trial that will follow AAML0531.
Selected Publications
Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood 2006; 108(1): 74-80. Epub 2006 Mar 14.
Aplenc R, Thompson J, Han P, La M, Zhao H, Lange BJ, Rebbeck T. MTHFR Polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005; 65(6): 2482-7.
Aplenc R, Lange BJ. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol. 2004; 125(4): 421-34.
Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, Blackwood MA, Lange B, Rebbeck T. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukemia. Br J Haematol. 2003; 122(2): 240-4.
